Back to Archived News
Biomoda Files Patent Protection to Speed Up Marketing of Its Lung Cancer Detection Technology
Thursday, June 14, 2007
Alburquerque, NM -- Biomoda, Inc. (Bulletin Board: BMOD) , Albuquerque, New Mexico, (www.biomoda.com), maker of patented early lung cancer detection testing and other cancer diagnostic technology, disclosed today that it is again expanding its intellectual property portfolio with an additional unique patent pending to enhance the stability and greatly increase the shelf-life of its assay. This potentially extraordinary step is looked to both save large sums in testing and expedite bringing to market of Biomoda's patented porphyrin molecule to detect different cell variations of lung cancer.
"Our development work continues to create new methodologies which are not obvious or known. We intend to vigorously protect and capitalize through patent protection," said John Cousins, President of Biomoda.
"This new patent details a number of ways that our onco-labeling solutions have been substantially enhanced," added Dr. Herbert Whitaker, Biomoda's Executive Vice-President and Director of Research. Leslie Robins, Biomoda's Vice-President noted: "It has been a very costly approach (nearly $3,000,000) and it has slowed the Company's entering the marketplace. However, now the Company is firmly in a position to deal with much larger organizations without fear of risking its exclusive position."
John Cousins added: "This additional patent, filed yesterday in Washington D.C., only weeks after the Company's most recent patent filing, underscores the critical importance of protecting and preparing to capitalize on our valuable proprietary technology. We are completing the steps in the Company's plan to link a chain or series of patents which will very soon allow the Company to discuss and disclose its research and aggressively negotiate joint ventures with absolute patent protection in place."
"Safe Harbor" Statement: This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are naturally subject to uncertainty and changes in circumstances. Actual results may vary materially from expectations contained herein. Biomoda is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise. Biomoda, Inc.
Contact: John Cousins of Biomoda, Inc., +1-505-821-0875
Back to Archived News